Search - tctmd.com

Displaying 121 - 140 of 487

Sort: Relevancy | Date

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

Shelley Wood

June 28, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2019

Caitlin E. Cox

May 31, 2019

News Industry News

EFFPAC RCT 24-month has revealed in EuroPCR 2019 that Luminor DCB demonstrate a non-increase of risk of death at 24-month follow-up

May 23, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News EuroPCR 2019

BASKET-SMALL 2 Angiographic Substudy Supports Safety of DCBs in Small Coronary Vessels

L.A. McKeown

May 22, 2019

News Conference News EuroPCR 2019

Drug-Coated Balloons in STEMI ‘Safe and Feasible’ in Specific Circumstances: REVELATION

L.A. McKeown

May 22, 2019

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

Presentation ARCH 2019

Paclitaxel DCB: Back to the Dark Ages for PAD?

Presenter: George S. Chrysant

April 12, 2019

Presentation CIT 2019

New Drug-Coated Balloon Technologies: Limus and Beyond

Presenter: Bruno Scheller

March 28, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for February 2019

Shelley Wood

March 01, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

L.A. McKeown

February 20, 2019

Advertisement

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

TCTMD’s Top 10 Most Popular Stories for June 2019

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

TCTMD’s Top 10 Most Popular Stories for May 2019

EFFPAC RCT 24-month has revealed in EuroPCR 2019 that Luminor DCB demonstrate a non-increase of risk of death at 24-month follow-up

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

BASKET-SMALL 2 Angiographic Substudy Supports Safety of DCBs in Small Coronary Vessels

Drug-Coated Balloons in STEMI ‘Safe and Feasible’ in Specific Circumstances: REVELATION

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Paclitaxel DCB: Back to the Dark Ages for PAD?

New Drug-Coated Balloon Technologies: Limus and Beyond

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

TCTMD’s Top 10 Most Popular Stories for February 2019

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content